Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and immunological diseases. Enanta’s research and development efforts include programs in the following disease areas: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19) and hepatitis B Virus (HBV) and chronic spontaneous urticaria (CSU).

Learn More »

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

February 7, 2024
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
February 6, 2024
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Upcoming Events